Found: 52
Select item for more details and to access through your institution.
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis.
- Published in:
- Rheumatology, 2024, v. 63, n. 11, p. 3124, doi. 10.1093/rheumatology/keae150
- By:
- Publication type:
- Article
The sGC stimulator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanisms.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-07391-1
- By:
- Publication type:
- Article
Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
- Published in:
- BJU International, 2006, v. 98, n. 6, p. 1259, doi. 10.1111/j.1464-410X.2006.06501.x
- By:
- Publication type:
- Article
No Plastic Responses to Experimental Manipulation of Sperm Competition per se in a Free-Living Flatworm.
- Published in:
- Ethology, 2010, v. 116, n. 4, p. 292, doi. 10.1111/j.1439-0310.2010.01746.x
- By:
- Publication type:
- Article
The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator.
- Published in:
- Frontiers in Physiology, 2020, v. 11, p. 1, doi. 10.3389/fphys.2020.00345
- By:
- Publication type:
- Article
Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator.
- Published in:
- Journal of Pathology, 2022, v. 256, n. 4, p. 442, doi. 10.1002/path.5859
- By:
- Publication type:
- Article
Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 15, p. 8016, doi. 10.3390/ijms22158016
- By:
- Publication type:
- Article
The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.
- Published in:
- International Journal of Molecular Sciences, 2018, v. 19, n. 6, p. 1712, doi. 10.3390/ijms19061712
- By:
- Publication type:
- Article
Experimental evidence that a combination of sGC stimulator BAY 60-4552 and PDE5 inhibitor vardenafil could salvage ED-patients with insufficient response to PDE5 inhibitors after cavernous nerve injury.
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Cyclic CMP and cyclic UMP: new (old) second messengers.
- Published in:
- 2011
- By:
- Publication type:
- Abstract
The use of PDE5 inhibitors in the treatment of benign prostate hyperplasia and lower urinary tract symptoms: preclinical evidences.
- Published in:
- 2007
- By:
- Publication type:
- Abstract
Determinants of female fecundity in a simultaneous hermaphrodite: the role of polyandry and food availability.
- Published in:
- Evolutionary Ecology, 2011, v. 25, n. 1, p. 203, doi. 10.1007/s10682-010-9402-5
- By:
- Publication type:
- Article
cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function.
- Published in:
- Nature Medicine, 2012, v. 18, n. 2, p. 252, doi. 10.1038/nm.2634
- By:
- Publication type:
- Article
Effects of PDE5 Inhibitors and sGC Stimulators in a Rat Model of Artificial Ureteral Calculosis.
- Published in:
- PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0141477
- By:
- Publication type:
- Article
sGC stimulation lowers elevated blood pressure in a new canine model of resistant hypertension.
- Published in:
- Hypertension Research, 2021, v. 44, n. 12, p. 1568, doi. 10.1038/s41440-021-00748-5
- By:
- Publication type:
- Article
Increased pulmonary prostacyclin synthesis in rats with chronic hypoxic pulmonary hypertension
- Published in:
- Cardiovascular Research, 2002, v. 55, n. 1, p. 171, doi. 10.1016/S0008-6363(02)00318-8
- By:
- Publication type:
- Article
Soluble Guanylate Cyclase Agonists Induce Bronchodilation in Human Small Airways.
- Published in:
- American Journal of Respiratory Cell & Molecular Biology, 2020, v. 62, n. 1, p. 43, doi. 10.1165/rcmb.2019-0001OC
- By:
- Publication type:
- Article
Soluble Guanylate Cyclase Agonists Induce Bronchodilation in Human Small Airways.
- Published in:
- 2020
- By:
- Publication type:
- Chart/Diagram/Graph
Nitric Oxide-Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease.
- Published in:
- American Journal of Respiratory Cell & Molecular Biology, 2018, v. 58, n. 5, p. 636, doi. 10.1165/rcmb.2017-0292OC
- By:
- Publication type:
- Article
Cyclic AMP stimulates renin gene transcription in juxtaglomerular cells.
- Published in:
- Pflügers Archiv: European Journal of Physiology, 2002, v. 444, n. 3, p. 335, doi. 10.1007/s00424-002-0818-9
- By:
- Publication type:
- Article
cGMP-Prkg1 signaling PDE5 inhibition shelter cochlear hair cells and hearing function.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Soluble Guanylyl Cyclase Stimulator Improves Contracting Skeletal Muscle Oxygen Pressures in Heart Failure Rats.
- Published in:
- FASEB Journal, 2022, v. 36, p. N.PAG, doi. 10.1096/fasebj.2022.36.S1.R2143
- By:
- Publication type:
- Article
Contracting Skeletal Muscle Oxygen Pressures in Rats with Heart Failure: Impact of Soluble Guanylyl Cyclase Activator.
- Published in:
- FASEB Journal, 2021, v. 35, p. N.PAG, doi. 10.1096/fasebj.2021.35.S1.04903
- By:
- Publication type:
- Article
Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC.
- Published in:
- Respiratory Research, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s12931-022-02189-1
- By:
- Publication type:
- Article
The 10th International Conference on cGMP 2022: recent trends in cGMP research and development—meeting report.
- Published in:
- Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, v. 396, n. 8, p. 1669, doi. 10.1007/s00210-023-02484-8
- By:
- Publication type:
- Article
Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease.
- Published in:
- Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, v. 394, n. 12, p. 2363, doi. 10.1007/s00210-021-02149-4
- By:
- Publication type:
- Article
cGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development.
- Published in:
- Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, v. 393, n. 2, p. 287, doi. 10.1007/s00210-019-01779-z
- By:
- Publication type:
- Article
Correction to: Meeting report of the 8<sup>th</sup> International Conference on "cGMP BcGMP: generators, effectors, and therapeutic implications" at Bamberg, Germany, from June 23 to 25, 2017.
- Published in:
- Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, v. 391, n. 3, p. 347, doi. 10.1007/s00210-018-1472-x
- By:
- Publication type:
- Article
Meeting report of the 8 International Conference on cGMP 'cGMP: generators, effectors, and therapeutic implications' at Bamberg, Germany, from June 23 to 25, 2017.
- Published in:
- Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, v. 390, n. 12, p. 1177, doi. 10.1007/s00210-017-1429-5
- By:
- Publication type:
- Article
From bedside to bench-meeting report of the 7th International Conference on cGMP 'cGMP: generators, effectors and therapeutic implications' in Trier, Germany, from June 19th to 21st 2015.
- Published in:
- Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, v. 388, n. 12, p. 1237, doi. 10.1007/s00210-015-1176-4
- By:
- Publication type:
- Article
Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy.
- Published in:
- ESC Heart Failure, 2020, v. 7, n. 6, p. 3983, doi. 10.1002/ehf2.12996
- By:
- Publication type:
- Article
Additive effects of the Rho kinase inhibitor Y-27632 and vardenafil on relaxation of the corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure.
- Published in:
- BJU International, 2017, v. 119, n. 2, p. 325, doi. 10.1111/bju.13691
- By:
- Publication type:
- Article
Soluble GC stimulators and activators: Past, present and future.
- Published in:
- British Journal of Pharmacology, 2024, v. 181, n. 21, p. 4130, doi. 10.1111/bph.15698
- By:
- Publication type:
- Article
Identification and characterization of the new generation soluble guanylate cyclase stimulator BAY‐747 designed for the treatment of resistant hypertension.
- Published in:
- British Journal of Pharmacology, 2023, v. 180, n. 19, p. 2500, doi. 10.1111/bph.16142
- By:
- Publication type:
- Article
Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney.
- Published in:
- British Journal of Pharmacology, 2022, v. 179, n. 11, p. 2476, doi. 10.1111/bph.15586
- By:
- Publication type:
- Article
Mind the gap (junction): cGMP induced by nitric oxide in cardiac myocytes originates from cardiac fibroblasts.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The nitric oxide–soluble guanylate cyclase–cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
- Published in:
- European Respiratory Review, 2024, v. 33, n. 171, p. 1, doi. 10.1183/16000617.0183-2023
- By:
- Publication type:
- Article
Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
- Published in:
- Current Urology Reports, 2008, v. 9, n. 4, p. 295, doi. 10.1007/s11934-008-0052-x
- By:
- Publication type:
- Article
New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventions.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Soluble Guanylate Cyclase Stimulator Vericiguat Enhances Long-Term Memory in Rats without Altering Cerebral Blood Volume.
- Published in:
- Biomedicines, 2021, v. 9, n. 8, p. 1047, doi. 10.3390/biomedicines9081047
- By:
- Publication type:
- Article
Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.
- Published in:
- American Journal of Nephrology, 2021, v. 52, n. 8, p. 642, doi. 10.1159/000516213
- By:
- Publication type:
- Article
Human cyclic nucleotide phosphodiesterases possess a much broader substrate-specificity than previously appreciated
- Published in:
- FEBS Letters, 2011, v. 585, n. 20, p. 3259, doi. 10.1016/j.febslet.2011.09.004
- By:
- Publication type:
- Article
Inhibition of the TGFβ signalling pathway by cGMP and cGMP-dependent kinase I in renal fibrosis.
- Published in:
- FEBS Open Bio, 2017, v. 7, n. 4, p. 550, doi. 10.1002/2211-5463.12202
- By:
- Publication type:
- Article
The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 17, p. 13226, doi. 10.3390/ijms241713226
- By:
- Publication type:
- Article
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators.
- Published in:
- Biological Chemistry, 2018, v. 399, n. 7, p. 679, doi. 10.1515/hsz-2018-0155
- By:
- Publication type:
- Article
cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway.
- Published in:
- Basic Research in Cardiology, 2018, v. 113, n. 4, p. 1, doi. 10.1007/s00395-018-0679-9
- By:
- Publication type:
- Article
Urinary miRNA Profiles in Chronic Kidney Injury—Benefits of Extracellular Vesicle Enrichment and miRNAs as Potential Biomarkers for Renal Fibrosis, Glomerular Injury, and Endothelial Dysfunction.
- Published in:
- Toxicological Sciences, 2022, v. 187, n. 1, p. 35, doi. 10.1093/toxsci/kfac028
- By:
- Publication type:
- Article
Soluble guanylate cyclase activator BAY 54–6544 improves vasomotor function and survival in an accelerated ageing mouse model.
- Published in:
- Aging Cell, 2022, v. 21, n. 9, p. 1, doi. 10.1111/acel.13683
- By:
- Publication type:
- Article
Urinary cGMP predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus before exposure to contrast medium.
- Published in:
- PLoS ONE, 2018, v. 13, n. 4, p. 1, doi. 10.1371/journal.pone.0195828
- By:
- Publication type:
- Article